How Kenya has become a clinical logistics hub for sub-Saharan Africa
Sub-Saharan Africa holds significant potential for clinical trials, with Kenya growing in status as a key logistics location to unlock…
Partner Content
-
-
Seeing the full patient journey
Combining longitudinal claims data with deeper inpatient detail supports stronger real-world evidence for life sciences and medical device research. MarketScan…
-
Transitioning from lab bench to GMP: What research scientists should know about manual aseptic filling
Many breakthrough therapies originate in research labs: academic institutions, biotech startups, and translational centers. The research-grade environments in which these…
-
Retatrutide peptide: A quality-control checklist for sourcing research-grade material
Few research compounds have drawn as much procurement traffic in the past two years as retatrutide. It is a single…
-
Pharma’s supplier sprawl problem: When more vendors create less control
Many pharmaceutical companies have steadily accumulated logistics partners as each product launch, market entry or acquisition added another provider into…
-
Can smarter technology selection help de-risk small-molecule development?
For a small-molecule drug candidate, a compound must dissolve, reach the required exposure, remain stable and be manufactured consistently at…
-
Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
New biologics, expanding indications, and rapid growth in GLP-1 therapies are bringing effective treatments to unprecedented numbers of patients. Yet…
-
Leading CDMO to attend CPHI Milan 2026 in Italy
Globally renowned contract development and manufacturing organisation (CDMO) Piramal Pharma Solutions (PPS) will showcase its expertise at the upcoming CPHI…
-
Beyond OEB5: Is OEB6 really the next standard for high-potency pharma?
Few areas of pharmaceutical manufacturing have attracted as much investment in recent years as high-potency containment. The expansion of oncology…
-
Oral solid dose at a turning point: Scaling for the next generation of therapies
As the first oral GLP-1 receptor agonists launch in 2026, we are reminded yet again of the enduring importance of…